Garry Nolan is currently a Senior Advisor at Arsenal Capital Partners. Garry has also previously worked at Apprise Biotech, Inc, Nodality Inc., and Rigel.
Garry Nolan's most notable previous position was at Rigel, where they were the Scientific Founder. There, they created original technology for peptide expression/screening inside cells as drug surrogate. This technology was used to make viruses that made cells "healthier". Garry Nolan was at Rigel from March 1995 to March 2001.
Before Rigel, Garry Nolan worked at Stanford University.
Garry Nolan pursued a postdoc fellowship in biochemistry at the Massachusetts Institute of Technology after receiving their Ph.D. in genetics from Stanford University School of Medicine. Garry completed their undergraduate degree in genetics at Cornell University.